Integrin alpha 4 beta 1 Overview
Molecule Name
Integrin alpha-4/beta-1
Synonyms
Integrin alpha 4 beta 1,ITGA4&ITGB1
Drug Development Progress
Drugs in Clinical Trials6
Approved Drugs3
Highest Development StageApproved
Target Synonym
Integrin alpha4beta1
Background
Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.
Integrin alpha 4 beta 1 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Natalizumab biosimilar (GENERIUM Pharmaceuticals) | GNR-093 | Phase 3 Clinical | Generium Pharmaceuticals | Multiple Sclerosis | Details |
| Avicursen | TV-1102; ATL/TV-1102; ATL-1102; ISIS-107248 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Multiple Sclerosis; Muscular Dystrophy, Duchenne | Details |
| Alintegimod | 7HP349; 7-HP-349; 7HP-349 | Phase 2 Clinical | 7 Hills Pharma LLC | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis | Details |
| LLP2A alendronate | Phase 1 Clinical | University Of California | Bone Diseases; Bone Diseases, Metabolic; Osteonecrosis; Osteoporosis | Details | |
| ABBV-243 | ABBV-243 | Phase 1 Clinical | Abbvie Inc | Details | |
| RBx-7796 | RBx-7796 | Clinical | Sun Pharmaceutical Industries Ltd | Asthma; Rhinitis, Allergic | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | Details |
| Natalizumab biosimilar (Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Multiple Sclerosis; Crohn Disease | Sandoz Inc | 2023-08-24 | Crohn Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | Details |
| Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Crohn Disease; Multiple Sclerosis | Biogen Idec | 2004-11-23 | Arthritis, Rheumatoid; Crohn Disease; Demyelinating Diseases; Epilepsies, Partial; Graft vs Host Disease; Ischemic Stroke; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myositis, Inclusion Body | Details |